Kornimate/medical-research-clean huggingface dataset:
comparison of serum sirt-1 and mmp-9 levels of patients with bronchiectasis and healthy controls

Conditions: Bronchiectasis Adult

Summary: the purpose of this a cross-sectinol study is to measure the levels of mmp-9 and sirt-1 levels in patients with bronchiectasis and healthy controls. the aim is to compare the serum levels of these molecules between patients and controls. * is the mmp-9 level increasing or decreasing? * is the sirt-1 level increasing or decreasing in patients? * is the disease related to age and gender? participants will only have one 5 ml blood sample drawn when they visit the chest illness clinic. molecule levels will be measured in this blood's serum. the patient group participants will be scanned once with high-resolution chest ct. apart from this, comparisons will be made using the age and gender information of the participants.

in the overall study population of 60 subjects who applied to the sivas cumhuriyet university faculty of medicine research and practice hospital chest diseases clinic. the study population was selected regardless of age and gender. participants selected bronchiectasis patients (n=30) who had symptoms (cough, sputum production) and had their diagnosis confirmed by a chest high-resolution ct scan within the previous year. the study excluded individuals with bronchiectasis not associated with cystic fibrosis and who had a worsening episode (according to the 2017 european respiratory society expert consensus criteria) (16) or had taken antibiotics during the previous four weeks. the study enrolled healthy controls (n=30) through advertisements who had acceptable chest x-ray and spirometry results and no lower airway symptoms or serious systemic disorders. the study eliminated individuals who were pregnant or nursing, as well as those with low comprehension. sirt-1 and mmp-9 levels in the serum of the study group were determined by the elisa method.

Eligibility criteria:
inclusion criteria: * bronchiectasis patients who were symptoms (cough, sputum production) * individuals whose diagnosis was confirmed by a high-resolution chest ct scan taken within the previous year exclusion criteria: * individuals with bronchiectasis associated with cystic fibrosis and who had a worsening episode * individuals who were pregnant or nursing * those with low comprehension * taken antibiotics during the previous four weeks

Keywords: bronchiectasis mmp-9 sirt-1
socket preservation using dentin graft autogenous dentin graft with collagen sponge on dental implant stability autogenous tooth graft with collagen sponge on dental implant stability

Conditions: Bone Loss; Bone Remodeling Disorder; Bone Resorption

Summary: the present study was performed to evaluate socket preservation using collagen sponge with autogenous dentin graft versus collagen sponge with de-mineralised freez-dried bone graft on dental implant stability

in our study we made socket preservation using two different grafts in two groups. before grafting we took cbct we used autogenous dentin graft covered by collagen sponge in one group and demineralized freeze - dried allograft covered with collagen sponge in the other group. after 6 months we took another cbct to assist the dimensional changes and bone density in the alveolar socket after grafting we inserted the implant and during insertion we took a core biopsy with trephine bur with external diameter 3 mm for histological analysis. after implant insertion we assisted the stability using rfa.

Eligibility criteria:
inclusion criteria: * patients are free from any systemic diseases. * patients with good oral hygiene. * age range from 25-50 years. * adequate inter arch space . exclusion criteria: * medications that may affect bone turnover, and bone metabolic diseases. * smoker patients and alcoholics. * patients with parafunctional habits. * patients with active acute infection related to tooth of interest. * patients with a lack of compliance, and serious mental or psychological problems. * pregnant females.

Keywords: socket preservation alveolar ridge defect dentin graft demineralized freeze dried allograft
open label trial to evaluate the adhesion of tk-254rx in healthy volunteers.

Conditions: Healthy

Summary: this study is a multi center, multiple dose, open label trial to evaluate the adhesion of tk-254rx in healthy volunteers. the primary purpose of this study is to evaluate the adhesion of tk-254rx. secondary purpose is to show tk-254rx is safe and to explore and compare adhesion assessment methods.


Eligibility criteria:
inclusion criteria: * age: 18 to 64 years * good state of health * non-smoker or ex-smoker for at least 3 months * written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial exclusion criteria: the following must not apply: * any injury of body which may induce the restriction of body movement * excessively hairy skin at application site * current skin disorder or shaving hair at application site * history of excessive sweating/hyperhidrosis inclusive of application site * participation in a clinical study within 30 days before inclusion in the study or concomitantly * drug or alcohol abuse in the opinion of the investigator * pregnant and lactating women * women of child-bearing potential who do not agree to apply highly effective contraceptive methods * known hypersensitivity to active ingredient, its racemate or one of the excipients of the tk-254rx * existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient * existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient * known liver or kidney insufficiency * existing gastrointestinal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient * history of relevant cns and/or psychiatric disorders and/or currently treated cns and/or psychiatric disorders * systolic blood pressure \ 139 mmhg * diastolic blood pressure \ 89 mmhg * pulse rate \ 90 bpm * subjects who use any impermissible medication
pancreatic cancer models developed from eus guided biopsy tissue

Conditions: Pancreatic Cancer; Pancreatic Adenocarcinoma; Pancreatic Cyst

Summary: pancreatic cancer is a very aggressive cancer. over the past 40 years there has not been much progress made in reducing deaths from this cancer. recently, new models of pancreatic cancers have been generated from mouse and human tissues. these models have used larger pieces of tissues taken from surgical removal of pancreatic cancers. the purpose of this study is to determine whether these new pancreatic cancer models can be generated from the small biopsies we take to make the diagnosis of the pancreatic mass.

the endoscopic ultrasound guided pancreatic biopsy tissue collected for only research purposes will be used to generate organoids in a in-vivo and in-vitro setting. the development of these methods may help scientists identify new treatments for pancreatic cancer and to potentially develop more personalized approaches to treating pancreatic cancer.

Eligibility criteria:
inclusion criteria: 1. patients who are scheduled for an eus-fnb of pancreatic mass(es) suspicious for pancreatic ductal adenocarcinoma performed by a member of the stony brook interventional endoscopy section of the division of gastroenterology and hepatology 1. age ≥ 18 years 2. literate and able/willing to provide informed consent for participation in research. exclusion criteria: 1. age \< 18 years 2. not literate or unable/unwilling to provide informed consent for eus-fnb research biopsies 3. pregnancy as determined by serum or urine hcg test performed as standard of clinical care for all women of childbearing age and documented on subjects' electronic medical record
rifabutin-containing triple therapy for treatment of helicobacter pylori

Conditions: Helicobacter Pylori Infection

Summary: rifabutin has good chemical stability and low drug resistance rate in acidic gastric environment. therefore, it is often used in combination with amoxicillin proton pump inhibitor for the rescue treatment of helicobacter pylori. the purpose of this study was to evaluate the efficacy and safety of rifabutin-containing triple therapy versus classical bismuth-containing quadruple therapy as rescue therapy for the eradication of refractory helicobacter pylori


Eligibility criteria:
inclusion criteria: * ability and willingness to participate in the study and to sign and give informed consent * confirmed h. pylori infection and with previous treatment experience exclusion criteria: * less than 18 years old * with previous gastric surgery * previous history of tuberculosis * major systemic diseases * pregnancy or lactation * allergy to any of the study drugs administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion

Keywords: helicobacter pylori therapy
intraprostatic botulinum toxin type "a" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy

Conditions: Benign Prostatic Hyperplasia (BPH); Benign Prostatic Enlargement (BPE)

Summary: the injection of botulinum neurotoxin a into the prostate represents an alternative, minimal invasive treatment in patient with lower urinary tract symptoms (luts) associated to benign prostatic hyperplasia (bph). objective: to evaluate the effectiveness of bta in treating patients with symptomatic bph and unsatisfactory response to combined medical therapy.


Eligibility criteria:
inclusion criteria: * moderate-to-severe luts as determined by the international prostate symptom score * mean peak urinary flow rate of no more than 15 ml/s with a voided volume of at least 150 ml, or postvoid residual urine volume (pvr) of more than 100 ml and urodynamic parameters indicative of bladder outlet obstruction (boo) according to international continence society exclusion criteria: * patients with neurogenic voiding disorders, prostate or bladder cancer, bladder stones, urethral stricture, chronic bladder catheterization were excluded from the study.
powered echelon device in vats surgery

Conditions: Non-small Cell Lung Cancer (NSCLC)

Summary: this study aims to collect real world outcomes of video-assisted thoracoscopic surgery (vats) for lung cancer (lobectomy, wedge resection) using echelon flex™ powered endopath® staplers 45 mm and/or 60 mm (study devices).


Eligibility criteria:
inclusion criteria: * suspected or confirmed nsclc (up to and including stage ii) * scheduled for lung resection surgery (lobectomy or wedge resection) involving only one lobe of the lung * performance status 0-1 (eastern cooperative oncology group classification) * asa score \< 3 * no prior history of vats or open lung surgery * willing to give consent and comply with study-related evaluation and treatment schedule exclusion criteria: * active bacterial infection or fungal infection; * systemic administration (intravenous or oral) of steroids (within 30 days prior to study procedure) * chemotherapy or radiation therapy for lung cancer may not be performed for 30 days prior to the procedure * scheduled concurrent surgical procedure other than wedge resection or lobectomy (central venous access - e.g. port placement, mediastinoscopy with lymph node sampling, and vats lymphadenectomy are allowed) * pregnancy * physical or psychological condition which would impair study participation; * the patient is judged unsuitable for study participation by the investigator for any other reason; or * unable or unwilling to attend follow-up visits and examinations
investigation of efficacy and safety of botulinum toxin a (botox-allergan inc) in migraine headaches

Conditions: Refractory Migraine

Summary: the hypothesis of this study is that injection of botulinum toxin a into the muscles around the head (frontal, temporal, posterior neck, occipital) can reduce the intensity and frequency of migraine headaches by 50%.

contact pi for study details

Eligibility criteria:
inclusion criteria: * adults 18 and older * migraine for more than three months, that fail to respond to two or more major anti-migraine drug, meeting criteria of chronic migraine exclusion criteria: * age below 18 * pregnant or may become pregnant * disease of neuromuscular junction or drugs that affect n-m junction * allergy to botox * previous use of botox for migraine by similar methodology

Keywords: migraine, refractory migraine, pain, botulinum toxin , botox
sarcopenia prevalence in frail older adults. saf study

Conditions: Aging

Summary: the age-associated loss of lean mass is a defining parameter of sarcopenia and may lead to various negative health outcomes such as impairment of physical performance and disability. furthermore sarcopenia is considered to be one of the main factors in the pathogenesis of the frailty syndrome. however, for clinical use and for treatment and prevention strategies, reliable diagnostic criteria and cutpoints based on clinically relevant thresholds are indispensable. this topic has recently been addressed by the foundation for the national institutes of health sarcopenia project which identified cutpoints for appendicular lean mass (alm) below which older adults had a higher likelihood of clinically relevant weakness reflected by low grip strength. moreover, a low alm-to-body mass index (bmi) ratio (\<0.789 men and \<0.512 women) was found to be associated with increased likelihood for mobility impairment. in this context, the aim of this study is to study the prevalence of sarcopenia in a sample of community-dwelling frail and pre-frail older adults.


Eligibility criteria:
inclusion criteria: * aged 70 years and over, * living independently (adl score ≥ 5/6), * fail or pre-frail according to fried criteria, * informed written consent, * subjects affiliated to a social security. exclusion criteria: * robusts patients (no fried criteria), * other disorders that could interfere with the interpretation of the study (like visual or hearing impairments), * subjects under justice protection, * participation in another study at the same time.

Keywords: frail elderly sarcopenia
a study to evaluate the effectiveness and safety initiation and titration of insulin glargine (u300) in insulin-naïve patients with type 2 diabetes mellitus (t2dm) controlled on oral antidiabetic drug treatment in turkey

Conditions: Type 2 Diabetes Mellitus

Summary: primary objective: to assess the mean change in hba1c (glycated haemoglobin). secondary objectives: to evaluate the efficacy and safety of the titration of insulin glargine u300 in terms of: * targeted hba1c; * targeted fasting self- monitoring blood glucose (smbg); * hypoglycemic events; * adverse events; * quality of life assessment by dtsqs (diabetes treatment satisfaction questionnaire status) and dtsqc (diabetes treatment satisfaction questionnaire change); * blood glucose fluctuation by using continuous glucose monitoring system (cgms) in subgroup patients.

the total study duration per patient will be 27 weeks (2 weeks of screening, 24 weeks on treatment, and 1 week follow-up period).

Eligibility criteria:
inclusion criteria : * adult patients with type 2 diabetes mellitus (≥18 years of age). * type 2 diabetes mellitus diagnosis ≥1 year. * treated with ≥1 oral antidiabetics (±glucagon like peptid-1 (glp-1) analogue) without insulin, for at least 6 months and hba1c level between 8-11% (insulin-naïve). * stable antidiabetic treatment for at least 3 months. * willingness to adherence to treatment and titration (including self-injection, self- monitoring blood glucose \[smbg\]). * signed informed consent obtained. exclusion criteria: * age \<18 years old. * type 1 diabetes mellitus. * having secondary type 2 diabetes mellitus. * use of any insulin therapy including premix, basal plus/basal bolus regimen from the diagnosis. * history of hypoglycemia unawareness. * known hypersensitivity/intolerance to insulin glargine or any of its excipients. * have any condition (including known substance or alcohol abuse or psychiatric disorder) that precludes the patient from following and completing the study protocol. * use of systemic glucocorticoids for two weeks or more within 12 weeks prior to the time of screening. * pregnant or lactating women. * participation in another clinical trial. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
a study to assess safety, tolerability, and pharmacokinetics of abi-h3733 in healthy adults

Conditions: Chronic Hepatitis B

Summary: this study is designed to assess safety, tolerability, pharmacokinetics (pk), formulation (liquid and solid oral forms) and food effect of abi-h3733 in healthy participants. part 1 includes evaluation of the safety, tolerability, and pk of abi-h3733 during single ascending dose (sad) and multiple-ascending dose (mad) administration of the oral liquid formulation. part 2 includes assessment of a solid dosage formulation of abi-h3733 in participants under fasted conditions or after a high-fat meal. optional cohorts may be enrolled in parts 1 and 2 of the study to explore additional dose levels, solid oral dosage formulations, or for cohort expansion.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on physical exam, medical history, or clinical laboratory results at screening. exclusion criteria: * positive test results for human immunodeficiency virus (hiv) or hepatitis b or c. * history of or current persistent drug or alcohol abuse.
assessment of brain cognitive impairment in breast cancer

Conditions: Breast Cancer; Chemo-brain; Endocrine Therapy

Summary: to explore the cognitive impairment caused by chemotherapy and endocrine therapy in premenopausal breast cancer patients and to find biomarkers with early predictive effect on this cognitive impairment by using multimodal integrated pet/mri technology combined with psychobehavioral technology.

breast cancer is the most common type of cancer in women worldwide, and cancer-related cognitive impairment (crci) has become one of the most concerning clinical problems in breast cancer treatment. this project intends to use the combination of advanced pet/mri technology and psycho-behavioral methods to observe the cognitive impairment and the changes in brain structure, function and glucose metabolism caused by chemotherapy and endocrine therapy in premenopausal breast cancer patients, then looking for possible predictors, through early identification of patients at risk of cognitive decline after chemotherapy or endocrine therapy, to provide a scientific basis for the rational selection of breast cancer treatment plans in the future.

Eligibility criteria:
inclusion criteria: * patients with primary stage i-ii breast cancer. * premenopausal women (menopausal status determined by national comprehensive cancer network breast cancer guidelines criteria). * no treatment other than surgery has been started (if neoadjuvant chemotherapy is required before surgery, enroll before chemotherapy starts). * eastern cooperative oncology group score of 0-1 points. * can understand and complete various scales. * right handedness. * female subjects of childbearing potential must be willing to use a medically-approved high-efficiency contraceptive method (eg, intra-uterine device, birth control pill, or condom) for the duration of the study. * sign the informed consent and voluntarily participate in this clinical observation. exclusion criteria: * central nervous system (cns) disease, history of malignancy, chronic loss of consciousness, head trauma, and any disease affecting cognitive function. * current or former epilepsy, dementia, or learning disabilities. * past psychiatric history. * past history of malignancy. * mri related contraindications: pacemakers, defibrillators, hearing aids, insulin pumps, drug dose control devices and other metal implants; patients with severe hyperthermia; patients with claustrophobia.

Keywords: crci psycho-behavioral technology integrated pet/mri technology biomarkers
study to test the safety and efficacy of tvi-brain-1 as a treatment for recurrent grade iv glioma

Conditions: Grade IV Glioma; Grade IV Astrocytoma; Glioblastoma Multiforme

Summary: tvi-brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill large numbers of the cancer cells that are present in your body. tvi-brain-1 is designed to generate large numbers of those 'killer' white blood cells and to deliver those cells into your body so that they can kill your cancer cells.

the tvi-brain-1 treatment involves several steps. first, the patient's cancer will be surgically removed to provide cells for the vaccine. second, the patient will be vaccinated with the vaccine formulation. third, the patient's blood will be filtered for killer t cell precursors which will then be cultured and stimulated to reach a higher (killer) activity level. fourth, the activated cells will be infused into the patient's bloodstream so that they will be able to attack the cancer.

Eligibility criteria:
inclusion criteria: * age \> 18 * informed consent * diagnosis of grade iv glioma with progression following standard treatment. * must be able to tolerate surgery to provide tumor tissue for vaccine. * must be able to produce viable vaccine from tumor tissue. * karnofsky performance status must be 70 or greater. * negative hiv test. * negative for hepatitis b and c virus. * respiratory reserve must be reasonable. * sufficient renal function. * satisfactory blood counts. * negative pregnancy test for women of childbearing potential. exclusion criteria: * surgically removed cancer reveals that it is not grade iv glioma. * concomitant life-threatening disease. * active autoimmune disease. * currently receiving chemotherapy or biological therapy for the treatment of cancer. * currently receiving immunosuppressive drugs for any reason. * prior treatment with avastin or other anti-angiogenesis treatment within 6 months. * prior treatment with gliadel wafers. * corticosteroids beyond peri-operative period. * psychological, familial, sociological or geographical conditions that do not permit adequate medical follow-up and compliance with the study protocol.

Keywords: brain neoplasms central nervous system neoplasms brain diseases neoplasms nervous system neoplasms glioblastoma astrocytoma nervous system diseases central nervous system diseases glioma recurrent astrocytoma recurrent glioma cancer vaccine immunotherapy killer t cells activated t cells gm-csf activated lymphocytes